Fig. 1: Study schema and single cell transcriptomic analysis.

A Study design. Patients were assigned to one of the two treatment cohorts: citarinostat in combination with PVX-410 or citarinostat with PVX-410 and lenalidomide. PVX-410 was given as six doses of 0.8 mg (0.2 mg/peptide or 0.8 mg total) emulsified in Montanide ISA 720 VG (Seppic, Inc.), biweekly (W0, W2, W4, W6, W8, and W10) via subcutaneous injection followed by a single dose of PVX-410 during follow-up visits at month M4, M5, M6, M9, and M12; 3 cycles of citarinostat (180 mg QD PO for 21 days every 28 days) and lenalidomide (25 mg QD PO for 21 days every 28 days) were given to patients in the double and triple combination cohorts, respectively in conjunction with the initial 6 doses of PVX-410. Patients were followed for a total 15 months. Immune response was assessed at W0, W2, W4, W6, W8, W10, M4, M5, M6, M9, and M12. Bone marrow biopsy was performed at screening W-4 and post-treatment M4. B UMAP projection of PB immune cells for all the samples. Cells are clustered based on their phenotypes and eight major immune cell types are highlighted with different colors shown in the legend. C Credible intervals and FDR for the detailed immune phenotype enrichment. CI values higher than 0 indicates enrichment (growth) of particular cell type (y-axis) and less than 0 indicates decreases. Populations with false discovery rate < 25% are show with blue color CIs. D Boxplots for the significantly changed (except CD16 monocytes) populations shown in panel C. Boxplots on left are showing baseline samples and right showing 4-month samples. Y-axis for each cell type shows the relative frequency of a given cell population. E Relative abundance (y-axis) of various clone sizes (color codes) at baseline (left) and post-treatment (right). F Diversity index (each panel) scores (y-axis) for baseline and post-treatment samples. Samples are color coded and samples from the same patient are using the same color with two different shades.